Report for: Intravenous immunoglobulin and rituximab versus placebo treatment of antibody-associated psychosis: study protocol of a randomised phase IIa double-blinded placebo-controlled trial (SINAPPS2)

Title	Intravenous immunoglobulin and rituximab versus placebo treatment of antibody-associated psychosis: study protocol of a randomised phase IIa double-blinded placebo-controlled trial (SINAPPS2)
Published in	Trials, June 2019
DOI	10.1186/s13063-019-3336-1
Pubmed ID	31174586
Authors	Belinda Lennox, Ksenija Yeeles, Peter B. Jones, Michael Zandi, Eileen Joyce, Ly-Mee Yu, Giuliano Tomei, Rebecca Pollard, Sally-Anne Vincent, Mio Shimazaki, Iona Cairns, Francis Dowling, Thomas Kabir, Thomas R. E. Barnes, Anne Lingford Hughes, Akram A. Hosseini, Timothy Harrower, Camilla Buckley, Alasdair Coles

X Demographics

The data shown below were collected from the profiles of 20 X users who shared this research output. Click here to find out more about how the information was compiled.

Type	Count	As %
Members of the public	17	85%
Practitioners (doctors, other healthcare professionals)	3	15%

Mendeley readers

The data shown below were compiled from readership statistics for 59 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Country	Count	As %
Unknown	59	100%

Readers by professional status	Count	As %
Student > Master	9	15%
Researcher	5	8%
Student > Bachelor	5	8%
Student > Ph. D. Student	5	8%
Student > Doctoral Student	2	3%
Other	7	12%
Unknown	26	44%

Readers by discipline	Count	As %
Medicine and Dentistry	13	22%
Neuroscience	7	12%
Nursing and Health Professions	4	7%
Biochemistry, Genetics and Molecular Biology	3	5%
Psychology	2	3%
Other	2	3%
Unknown	28	47%

Intravenous immunoglobulin and rituximab versus placebo treatment of antibody-associated psychosis: study protocol of a randomised phase IIa double-blinded placebo-controlled trial (SINAPPS2)